This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The principle (intention to treat or treatment completers only) used in the analysis of effectiveness was not specified. The health outcome measures were the percentage of women who were spared a surgical procedure by US-guided core biopsy, the number of malignant lesions, and the percentage of recommended repeat biopsy.
Effectiveness results
The percentage of women who were spared a surgical procedure by US-guided core biopsy was 85% (128/151). The number of malignant lesions was 56 (37%). The percentage of recommended repeat biopsy was 10%.
Clinical conclusions
The frequency of obviating a surgical procedure with US-guided core biopsy in this study was comparable to the frequency of obviating a surgical procedure after stereotactic core biopsy of nonpalpable breast masses in previous studies.
Outcomes assessed in the review
The effectiveness data assessed by review were the frequency of spared surgical procedure and the rate of repeat biopsy for stereotactically guided core biopsy.
Study designs and other criteria for inclusion in the review
Not reported.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Three studies were included in the review.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The frequency of spared surgical procedure was 84% and 87% for stereotactically guided core biopsy reported from two different studies. The rate of repeat biopsy was 18%.
